Clinical Trials Browser

INDUSTRY × elotuzumab × Other hematologic neoplasm × Clear all

NCT04614636 2023-09-21

FT538 in Subjects With Advanced Hematologic Malignancies

Phase 1 Terminated

Other hematologic neoplasmPlasma cell

Multiple Myeloma, Leukemia, Myeloid, Acute, Neoplasms, Plasma Cell

NCT00742560 2018-01-10

A Phase 1b/2, Dose-Escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Relapsed Multiple Myeloma

Phase 2 Completed

101 enrolled 20 charts

Other hematologic neoplasmPlasma cell

Multiple Myeloma, Hematologic Neoplasms